Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01202760 · ClinicalTrials.gov registry record · Phase 3
A Rheumatoid Arthritis Study in Participants
A Phase 3 study, sponsored by Eli Lilly and Company.
- Completed
- Registry status
- Phase 3
- Development phase
- 1,004
- Enrollment target
NCT01202760: Completed Phase 3 study, sponsored by Eli Lilly and Company.
NCT01202760 is a Phase 3 study that has completed, run by Eli Lilly and Company. The registered enrollment target is 1,004 participants, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01202760, a Phase 3 study, has completed, sponsored by Eli Lilly and Company.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 1,004 participants
- Enrollment target
Study Summary
The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. This study is comprised of 2 periods: Period 1 - 24-week blinded treatment Period 2 - 48-week post-treatment follow-up
Primary Outcome
ACR20 Responder Index: Composite of clinical, laboratory, and functional measures of rheumatoid arthritis. ACR20 Responder: had \>=20% improvement from baseline in both 68 tender and 66 swollen joint counts and \>=20% improvement in at least 3 of 5 criteria: participant's and physician's global assessment of disease activity, Health Assessment Questionnaire-Disability Index (HAQ-DI) (which measured participants' perceived degree of difficulty performing daily activities), joint pain, and C-react
Interventions
- DRUG Placebo
- DRUG LY2127399
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 1,004 participants |
| Start Date | 2011-01 |
| Est. Completion | 2013-07 |
| Phase | Phase 3 |
What the finished NCT01202760 record still lists
NCT01202760 is an interventional study that assigns participants to a tested intervention. Its 1,004 participants enrollment target places it among the larger protocols in the corpus, above the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (30% higher).
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT01202760 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT01202760 about?
NCT01202760 is a clinical study titled "A Rheumatoid Arthritis Study in Participants". The primary purpose of this study is to help answer if LY2127399 is safe and effective in the treatment of rheumatoid arthritis with or without background disease-modifying anti-rheumatic drug (DMARD) therapy. This study is comprised of 2 periods: Period 1 - 24-week blinded treatment Period 2 - 4...
What is the current status of trial NCT01202760?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 1,004 participants. The study started on 2011-01. Estimated completion is 2013-07.
What interventions are being tested in trial NCT01202760?
The interventions under investigation include: Placebo (DRUG), LY2127399 (DRUG).
Who is sponsoring clinical trial NCT01202760?
This trial is sponsored by Eli Lilly and Company, which has 1,341 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT01202760's enrollment target sits among peer trials
1,004 295th of 2000 higher than 1,706 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04389632 · 1,006 participants · Phase 1
A Study of Sigvotatug Vedotin in Advanced Solid Tumors
- NCT06207864 · 1,001 participants · NA
Engagement of American Indians of Southwestern Tribal Nations in Cancer Genome Sequencing
- NCT07191782 · 1,008 participants · NA
Examining the Efficacy of the PRAISE With Coaching Program
- NCT00018044 · 1,000 participants
Study of Mycobacterial Infections
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia